Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission: results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: WFRF:(Andreasson Ulf) > Longitudinal minima...

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission : results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Schmitz, Alexander (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ Hosp, Denmark

Brondum, Rasmus Froberg (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ Hosp, Denmark

Johnsen, Hans Erik (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark; Nordic Myeloma Study Grp NMSG, Sweden

visa fler...

Mellqvist, Ulf-Henrik (författare): Nordic Myeloma Study Grp NMSG, Sweden; South Elvsborg Hosp, Sweden

Waage, Anders (författare): Nordic Myeloma Study Grp NMSG, Sweden; Norwegian Univ Sci & Technol, Norway; St Olavs Univ Hosp, Norway

Gimsing, Peter (författare): Nordic Myeloma Study Grp NMSG, Sweden; Univ Copenhagen, Denmark

Bruinink, Davine Hofste Op (författare): Erasmus MC, Netherlands

van der Velden, Vincent (författare): Erasmus MC, Netherlands

van der Holt, Bronno (författare): Erasmus MC, Netherlands; Erasmus MC Canc Inst, Netherlands

Hansson, Markus (författare): Nordic Myeloma Study Grp NMSG, Sweden; Skane Univ Hosp, Sweden

Andersen, Niels Frost (författare): Nordic Myeloma Study Grp NMSG, Sweden; Aarhus Univ Hosp, Denmark

Frolund, Ulf Christian (författare): Nordic Myeloma Study Grp NMSG, Sweden; Sjllands Univ Hosp, Denmark

Helleberg, Carsten (författare): Nordic Myeloma Study Grp NMSG, Sweden; Herlev Hosp, Denmark

Schjesvold, Fredrik H. (författare): Nordic Myeloma Study Grp NMSG, Sweden; Oslo Univ Hosp, Norway; Univ Oslo, Norway

Ahlberg, Lucia (författare): Region Östergötland, Hematologiska kliniken US,Nordic Myeloma Study Grp NMSG, Sweden

Gulbrandsen, Nina (författare): Nordic Myeloma Study Grp NMSG, Sweden; Oslo Univ Hosp, Norway; Univ Oslo, Norway

Andreasson, Bjorn (författare): Nordic Myeloma Study Grp NMSG, Sweden; NU Hosp Grp, Sweden

Lauri, Birgitta (författare): Nordic Myeloma Study Grp NMSG, Sweden; Sunderby Hosp, Sweden

Haukas, Einar (författare): Nordic Myeloma Study Grp NMSG, Sweden; Stavanger Univ Hosp, Norway

Bodker, Julie Stove (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ Hosp, Denmark

Roug, Anne Stidsholt (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark

Bogsted, Martin (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark

Severinsen, Marianne T. (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark

Gregersen, Henrik (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark; Nordic Myeloma Study Grp NMSG, Sweden

Abildgaard, Niels (författare): Nordic Myeloma Study Grp NMSG, Sweden; Odense Univ Hosp, Denmark

Sonneveld, Pieter (författare): Erasmus MC, Netherlands; European Myeloma Network EMN, Denmark

Dybkaer, Karen (författare): Aalborg Univ Hosp, Denmark; Aalborg Univ Hosp, Denmark; Aalborg Univ, Denmark

visa färre...

(creator_code:org_t)

2022-02-05
2022
Engelska.
Ingår i: BMC Cancer. - : BMC. - 1471-2407 .- 1471-2407. ; 22:1

Relaterad länk:: https://liu.diva-por... (primary) (Raw object); visa fler...; https://bmccancer.bi...; https://urn.kb.se/re...; https://doi.org/10.1...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Background: Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy. Presence of small number of cancer cells in the body after cancer treatment, called minimal residual disease, has been shown to be prognostic for progression-free and overall survival. However, for multiple myeloma, it is unclear whether patients attaining minimal residual disease negativity may be candidates for treatment discontinuation. We investigated, if longitudinal flow cytometry-based monitoring of minimal residual disease (flow-MRD) may predict disease progression earlier and with higher sensitivity compared to biochemical assessments. Methods: Patients from the Nordic countries with newly diagnosed multiple myeloma enrolled in the European-Myeloma-Network-02/Hovon-95 (EMN02/HO95) trial and undergoing bone marrow aspiration confirmation of complete response, were eligible for this Nordic Myeloma Study Group (NMSG) substudy. Longitdudinal flow-MRD assessment of bone marrow samples was performed to identify and enumerate residual malignant plasma cells until observed clinical progression. Results: Minimal residual disease dynamics were compared to biochemically assessed changes in serum free light chain and M-component. Among 20 patients, reaching complete response or stringent complete response during the observation period, and with >= 3 sequential flow-MRD assessments analysed over time, increasing levels of minimal residual disease in the bone marrow were observed in six cases, preceding biochemically assessed disease and clinical progression by 5.5 months and 12.6 months (mean values), respectively. Mean malignant plasma cells doubling time for the six patients was 1.8 months (95% CI, 1.4-2.3 months). Minimal malignant plasma cells detection limit was 4 x 10-5. Conclusions: Flow-MRD is a sensitive method for longitudinal monitoring of minimal residual disease dynamics in multiple myeloma patients in complete response. Increasing minimal residual disease levels precedes biochemically assessed changes and is an early indicator of subsequent clinical progression.

Hitta via bibliotek

BMC Cancer (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: BMC Cancer

Av lärosätet: Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission : results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Ämnesord

Nyckelord

Publikations- och innehållstyp

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Sök utanför SwePub